ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion

In today's ACT Brief, we examine how sustainability is shifting from compliance to a procurement driver, what infrastructure gaps remain in FDA's real-time pilot model, and regulatory guidance targeting unnecessarily restrictive cancer trial criteria.